These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33555543)

  • 21. BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma.
    Cybulska-Stopa B; Rogala P; Czarnecka AM; Galus Ł; Dziura R; Rajczykowski M; Kubiatowski T; Wiśniewska M; Gęga-Czarnota A; Teterycz P; Ziobro M; Suwiński R; Mackiewicz J; Rutkowski P
    Melanoma Res; 2020 Oct; 30(5):465-471. PubMed ID: 32221131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma.
    Aya F; Fernandez-Martinez A; Gaba L; Victoria I; Tosca M; Pineda E; Gascon P; Prat A; Arance A
    Clin Transl Oncol; 2017 Jan; 19(1):119-124. PubMed ID: 27147251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
    Valpione S; Carlino MS; Mangana J; Mooradian MJ; McArthur G; Schadendorf D; Hauschild A; Menzies AM; Arance A; Ascierto PA; Di Giacomo A; de Rosa F; Larkin J; Park JJ; Goldinger SM; Sullivan RJ; Xu W; Livingstone E; Weichenthal M; Rai R; Gaba L; Long GV; Lorigan P
    Eur J Cancer; 2018 Mar; 91():116-124. PubMed ID: 29360604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
    Diem S; Kasenda B; Spain L; Martin-Liberal J; Marconcini R; Gore M; Larkin J
    Br J Cancer; 2016 Feb; 114(3):256-61. PubMed ID: 26794281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response.
    Desvignes C; Abi Rached H; Templier C; Drumez E; Lepesant P; Desmedt E; Mortier L
    Melanoma Res; 2017 Jun; 27(3):281-287. PubMed ID: 28240681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study.
    Mastorakos P; Xu Z; Yu J; Hess J; Qian J; Chatrath A; Taylor DG; Kondziolka D; Warnick R; Chiang V; Sheehan J
    Neurosurgery; 2019 Apr; 84(4):868-880. PubMed ID: 29846702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
    Gambichler T; Iordanou M; Becker JC; Susok L
    Melanoma Res; 2024 Feb; 34(1):80-83. PubMed ID: 37924529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy.
    Weide B; Richter S; Büttner P; Leiter U; Forschner A; Bauer J; Held L; Eigentler TK; Meier F; Garbe C
    PLoS One; 2013; 8(11):e81624. PubMed ID: 24312329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
    de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
    Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
    Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
    [No Abstract]   [Full Text] [Related]  

  • 31. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
    Ackerman A; Klein O; McDermott DF; Wang W; Ibrahim N; Lawrence DP; Gunturi A; Flaherty KT; Hodi FS; Kefford R; Menzies AM; Atkins MB; Long GV; Sullivan RJ
    Cancer; 2014 Jun; 120(11):1695-701. PubMed ID: 24577748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
    Van Not OJ; van den Eertwegh AJM; Haanen JB; van Rijn RS; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; de Groot JWWB; Hospers GAP; Kapiteijn E; Bloem M; Piersma D; Stevense-den Boer M; Verheijden RJ; van der Veldt AAM; Wouters MWJM; Blokx WAM; Suijkerbuijk KPM
    Cancer; 2024 May; 130(9):1673-1683. PubMed ID: 38198485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should Targeted Therapy Be Continued in BRAF-Mutant Melanoma Patients after Complete Remission?
    Bédouelle E; Nguyen JM; Varey E; Khammari A; Dreno B
    Dermatology; 2022; 238(3):517-526. PubMed ID: 34818219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.
    Weide B; Elsässer M; Büttner P; Pflugfelder A; Leiter U; Eigentler TK; Bauer J; Witte M; Meier F; Garbe C
    Br J Cancer; 2012 Jul; 107(3):422-8. PubMed ID: 22782342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous blocking of the pan-RAF and S100B pathways as a synergistic therapeutic strategy against malignant melanoma.
    Wu KJ; Ho SH; Wu C; Wang HD; Ma DL; Leung CH
    J Cell Mol Med; 2021 Feb; 25(4):1972-1981. PubMed ID: 33377602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.
    Felix J; Cassinat B; Porcher R; Schlageter MH; Maubec E; Pages C; Baroudjian B; Homyrda L; Boukouaci W; Tamouza R; Bagot M; Caignard A; Toubert A; Lebbé C; Moins-Teisserenc H
    Int Immunopharmacol; 2016 Nov; 40():466-473. PubMed ID: 27728898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients.
    Deckers EA; Kruijff S; Brouwers AH; van der Steen K; Hoekstra HJ; Thompson JF; Vállez García D; Wevers KP
    Eur J Surg Oncol; 2020 Nov; 46(11):2147-2153. PubMed ID: 32819759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
    Kakavand H; Wilmott JS; Menzies AM; Vilain R; Haydu LE; Yearley JH; Thompson JF; Kefford RF; Hersey P; Long GV; Scolyer RA
    Clin Cancer Res; 2015 Jul; 21(14):3140-8. PubMed ID: 25609064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma.
    Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
    Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.
    Amini-Adle M; Khanafer N; Le-Bouar M; Duru G; Dalle S; Thomas L
    BMC Cancer; 2018 Jul; 18(1):705. PubMed ID: 29970025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.